Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 5, 2014, Pages 885-893

  Gordon, Stuart C ^a   Lamerato, Lois E ^a   Rupp, Loralee B ^a   Li, Jia ^a   Holmberg, Scott D ^b   Moorman, Anne C ^b   Spradling, Philip R ^b   Teshale, Eyasu H ^b   Vijayadeva, Vinutha ^c   Boscarino, Joseph A ^d   Henkle, Emily M ^e   Oja Tebbe, Nancy ^a   Lu, Mei ^a   Nerenz, David ^a   Akkerman, Nonna ^a   Cogan, Chad ^a   Zhang, Talan ^a   Larkin, Dana ^a   Daar, Zahra ^d   Leader, Joe ^d   Curry, Patrick ^d   Smith, Robert ^d   Vijayadeva, Vinutha X ^c   Nakasato, Cynthia ^c   Sylva, Kelly ^c   Parker, John ^c   Schmidt, Mark M ^c   Schmidt, Mark A ^e   Dodge, Tracy ^e   Donald, Judy ^e   Keast, Erin ^e   more..

^a HENRY FORD HEALTH SYSTEM   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c KAISER PERMANENTE   (United States)

^d GEISINGER HEALTH SYSTEM   (United States)

^e CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

Alanine Aminotransferase; Fibrosis; Liver Cancer; Tumor

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ENTECAVIR; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; TELBIVUDINE; TENOFOVIR; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RISK ASSESSMENT; RISK REDUCTION; UNITED STATES; VIRUS LOAD; ADOLESCENT; AGED; BIOSTATISTICS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; COMPLICATION; HEPATITIS B, CHRONIC; INCIDENCE; LIVER NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; TIME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BIOSTATISTICS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; RISK ASSESSMENT; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84899085087     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.09.062     Document Type: Article

References (19)

1. Lai C.L., Yuen M.F. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology 2013, 57:399-408.
2. Singal A.K., Salameh H., Kuo Y.F., et al. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther 2013, 38:98-106.
3. Kumada T., Toyoda H., Tada T., et al. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. JHepatol 2013, 58:427-433.
4. Wong G.L.H., Chan H.L.Y., Mak C.H., et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013, 58:1537-1547.
5. Hosaka T., Suzuki F., Kobayashi M., et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013, 58:98-107.
6. Wu C.Y., Chen Y.J., Ho H.J., et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 2012, 308:1906-1914.
7. Liaw Y.F., Sung J.J.Y., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. NEngl J Med 2004, 351:1521-1531.
8. Shamliyan T.A., MacDonald R., Shaukat A., et al. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med 2009, 150:111-124.
9. Sherman M. Does hepatitis B treatment reduce the incidence of hepatocellular carcinoma?. Hepatology 2013, 58:18-20.
10. Moorman A.C., Gordon S.C., Rupp L.B., et al. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the Chronic Hepatitis Cohort Study. Clin Infect Dis 2013, 56:40-50.
11. Austin P.C. The performance of different propensity-score methods for estimating relative risks. JClin Epidemiol 2008, 61:537-545.
12. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
13. Singal A.G., Volk M.L., Jensen D., et al. Asustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010, 8:280-288. 288.e1.
14. Lok A.S., Seeff L.B., Morgan T.R., et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009, 136:138-148.
15. Velázquez R.F., Rodríguez M., Navascués C.A., et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003, 37:520-527.
16. Fattovich G., Stroffolini T., Zagni I., et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127:S35-S50.
17. Dienstag J.L., Goldin R.D., Heathcote E.J., et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003, 124:105-117.
18. Van Zonneveld M., Zondervan P.E., Cakaloglu Y., et al. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine. Liver 2006, 26:399-405.
19. Spradling P.R., Rupp L., Moorman A.C., et al. Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis 2012, 55:1047-1055.